Department of Basic Pharmaceutical Sciences, Fred Wilson School of Pharmacy, High Point University, High Point, NC 27268, USA.
Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Biophys Chem. 2020 Dec;267:106477. doi: 10.1016/j.bpc.2020.106477. Epub 2020 Sep 20.
The peptide hormone amylin receptor is a complex of the calcitonin receptor (CTR) and an accessory protein called receptor activity-modifying proteins (RAMPs). The soluble extracellular domain (ECD) of CTR is an important binding site of peptide hormone calcitonin. RAMPs also have an ECD and the association of CTR ECD with RAMP ECD enhances the affinity of peptide hormone amylin. However, the mechanism of how RAMP ECD association enhances amylin affinity remains elusive. Here, we report evidence supporting direct molecular interaction between an antagonistic amylin analog AC413 and RAMP2 ECD. We measured FITC-labeled peptide affinity for purified receptor ECD using fluorescence polarization (FP). We first found that RAMP2 ECD addition to maltose-binding protein (MBP)-tagged CTR ECD and an engineered MBP-tagged RAMP2 ECD-CTR ECD fusion protein (MBP-RAMP2-CTR ECD fusion) enhanced AC413 affinity. This suggests that these recombinant ECD systems represent functional amylin receptors. Interestingly, AC413 C-terminal residue Tyr25 (Y25) to Pro mutation eliminated its selective affinity for the MBP-RAMP2-CTR ECD fusion suggesting the critical role of the AC413 C-terminal residue in amylin receptor selectivity. Our structural model of the RAMP2 ECD:CTR ECD complex predicted molecular interaction of AC413 C-terminal residue Y25 with RAMP2 Glu101 (E101). Our FP peptide-binding assay showed that the RAMP2 E101A mutation of MBP-RAMP2-CTR ECD fusion decreased AC413 affinity by 7-fold, while the affinity of AC413 with the Y25P mutation was minimally changed. Consistently, AC413 binding affinity for the MBP-free RAMP2-CTR ECD fusion protein was also markedly decreased by the RAMP2 E101A mutation, while the affinity of AC413 with the Y25P mutation was moderately decreased. Together, our results support the molecular interaction between the AC413 C-terminal residue Y25 and RAMP2 E101 expanding our understanding of how the accessory protein RAMP2 enhances affinity of peptide hormone amylin for its receptor.
肽激素胰岛淀粉样多肽受体是降钙素受体 (CTR) 和一种称为受体活性修饰蛋白 (RAMP) 的辅助蛋白的复合物。CTR 的可溶性细胞外结构域 (ECD) 是肽激素降钙素的重要结合位点。RAMP 也有一个 ECD,CTR ECD 与 RAMP ECD 的结合增强了肽激素胰岛淀粉样多肽的亲和力。然而,RAMP ECD 结合如何增强胰岛淀粉样多肽亲和力的机制仍不清楚。在这里,我们报告了支持拮抗胰岛淀粉样多肽类似物 AC413 与 RAMP2 ECD 之间直接分子相互作用的证据。我们使用荧光偏振 (FP) 测量 FITC 标记肽对纯化受体 ECD 的亲和力。我们首先发现,RAMP2 ECD 的添加到麦芽糖结合蛋白 (MBP)-标记的 CTR ECD 和工程 MBP-标记的 RAMP2 ECD-CTR ECD 融合蛋白 (MBP-RAMP2-CTR ECD 融合) 增强了 AC413 的亲和力。这表明这些重组 ECD 系统代表功能性胰岛淀粉样多肽受体。有趣的是,AC413 C 末端残基 Tyr25 (Y25) 到 Pro 的突变消除了其对 MBP-RAMP2-CTR ECD 融合的选择性亲和力,表明 AC413 C 末端残基在胰岛淀粉样多肽受体选择性中的关键作用。我们预测 RAMP2 ECD:CTR ECD 复合物的结构模型表明,AC413 C 末端残基 Y25 与 RAMP2 Glu101 (E101) 之间存在分子相互作用。我们的 FP 肽结合测定表明,MBP-RAMP2-CTR ECD 融合中 RAMP2 E101A 突变使 AC413 的亲和力降低了 7 倍,而 Y25P 突变的 AC413 亲和力变化很小。一致地,RAMP2 E101A 突变也显著降低了 AC413 与 MBP 游离 RAMP2-CTR ECD 融合蛋白的结合亲和力,而 Y25P 突变的亲和力则适度降低。总之,我们的结果支持 AC413 C 末端残基 Y25 与 RAMP2 E101 之间的分子相互作用,扩展了我们对辅助蛋白 RAMP2 如何增强肽激素胰岛淀粉样多肽与其受体亲和力的理解。